Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)

Ajai Chari, Maria-Victoria Mateos, Niels W. C. J. van de Donk, Jonathan L. Kaufman, Philippe Moreau, Albert Oriol, Torben Plesner, Lotfi Benboubker, Hareth Nahi, Jie Tang, Peter Hellemans, Brenda Tromp, Pamela L. Clemens, Andrew Farnsworth, Jesus F. San-Miguel, Saad Z. Usmani

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

OriginalsprogEngelsk
TidsskriftBlood
Vol/bind132
Udgave nummerSuppl. 1
ISSN0006-4971
DOI
StatusUdgivet - 29. nov. 2018
Begivenhed60th ASH Annual Meeting - San Diego, USA
Varighed: 1. dec. 20184. dec. 2018

Konference

Konference60th ASH Annual Meeting
LandUSA
BySan Diego
Periode01/12/201804/12/2018

Bibliografisk note

60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, DEC 01-04, 2018

Citationsformater

Chari, A., Mateos, M-V., van de Donk, N. W. C. J., Kaufman, J. L., Moreau, P., Oriol, A., Plesner, T., Benboubker, L., Nahi, H., Tang, J., Hellemans, P., Tromp, B., Clemens, P. L., Farnsworth, A., San-Miguel, J. F., & Usmani, S. Z. (2018). Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO). Blood, 132(Suppl. 1). https://doi.org/10.1182/blood-2018-99-113590